Bionor is a biopharmaceutical company with first mover potential to advance a possible functional HIV cure

Latest news

Hide mandatory notifications of trade

Bionor Pharma ASA – Extraordinary General Meeting

Financial .2016

(Oslo, Norway, 12 February 2016) Bionor Pharma ASA (OSE:BIONOR), a biopharmaceutical company focused on advancing a functional cure for HIV, has received a request from Lars Høie and certain other shareholders, who jointly hold approximately 30 per cent of the share capital in the company, that an extraordinary general meeting be held for the election of a new board of directors of the company.

Q4 and Full Year 2015 Interim Financial Report

Financial .2016

Bionor Pharma ASA
Interim Financial Report
1 January - 31 December 2015
Unaudited

Oslo, 12 February 2016

Bionor Pharma ASA completes extraordinary general meeting

Financial .2016

(Oslo, Norway, 11 February 2016) Bionor Pharma ASA ("Bionor" or the "Company", ticker "BIONOR") has completed the Extraordinary General Meeting (EGM) today which approved the Private Placement and Repair Issue announced on 27 January 2016. As proposed by the Company’s majority shareholder at the EGM, the EGM resolved not to allow oversubscription in the Repair Issue.

Bionor Pharma ASA – Extraordinary General Meeting

Financial .2016

(Oslo, Norway, 12 February 2016) Bionor Pharma ASA (OSE:BIONOR), a biopharmaceutical company focused on advancing a functional cure for HIV, has received a request from Lars Høie and certain other shareholders, who jointly hold approximately 30 per cent of the share capital in the company, that an extraordinary general meeting be held for the election of a new board of directors of the company.

Q4 and Full Year 2015 Interim Financial Report

Financial .2016

Bionor Pharma ASA
Interim Financial Report
1 January - 31 December 2015
Unaudited

Oslo, 12 February 2016

Bionor Pharma ASA completes extraordinary general meeting

Financial .2016

(Oslo, Norway, 11 February 2016) Bionor Pharma ASA ("Bionor" or the "Company", ticker "BIONOR") has completed the Extraordinary General Meeting (EGM) today which approved the Private Placement and Repair Issue announced on 27 January 2016. As proposed by the Company’s majority shareholder at the EGM, the EGM resolved not to allow oversubscription in the Repair Issue.

Go to news section